The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Critical aspects of the Bayesian approach to phase I cancer trials
Abstract
The Bayesian approach to finding the maximum‐tolerated dose in phase I cancer trials is discussed. The suggested approach relies on a realistic dose–toxicity model, allows one to include prior information, and supports clinical decision making by presenting within‐trial information in a transparent way. The modeling and decision‐making components are flexible enough to be extendable to more complex settings. Critical aspects are emphasized and a comparison with the continual reassessment method (CRM) is performed with data from an actual trial and a simulation study. The comparison revealed similar operating characteristics while avoiding some of the difficulties encountered in the actual trial when applying the CRM. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Monte Carlo Statistical Methods
Robert, C. P., & Casella, G. (2004) · Springer Texts in Statistics · doi:10.1007/978-1-4757-4145-2 · Cited by 4,271
Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2003) · Wiley eBooks · doi:10.1002/0470092602 · Cited by 1,673
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
A Method for Obtaining and Analyzing Sensitivity Data
Dixon, W. J., & Mood, A. M. (1948) · Journal of the American Statistical Association · doi:10.1080/01621459.1948.10483254 · Cited by 1,268
Bayesian Statistics without Tears: A Sampling–Resampling Perspective
Smith, A. F. M., & Gelfand, A. E. (1992) · The American Statistician · doi:10.1080/00031305.1992.10475856 · Cited by 1,003
Design and Analysis of Phase I Clinical Trials
Storer, B. E. (1989) · Biometrics · doi:10.2307/2531693 · Cited by 930
Cancer phase I clinical trials: efficient dose escalation with overdose control
Babb, J., Rogatko, A., & Zacks, S. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980530)17:10<1103::aid-sim793>3.0.co;2-9 · Cited by 623
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Cheung, Y. K., & Chappell, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.01177.x · Cited by 545
Continual Reassessment Method: A Likelihood Approach
O'Quigley, J., & Shen, L. Z. (1996) · Biometrics · doi:10.2307/2532905 · Cited by 382
Practical modifications of the continual reassessment method for phase i cancer clinical trials
Faries, D. (1994) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409408835079 · Cited by 238
Dose‐Finding with Two Agents in Phase I Oncology Trials
Thall, P. F., Millikan, R. E., Mueller, P., & Lee, S. (2003) · Biometrics · doi:10.1111/1541-0420.00058 · Cited by 208
Competing designs for phase I clinical trials: a review
Rosenberger, W. F., & Haines, L. M. (2002) · Statistics in Medicine · doi:10.1002/sim.1229 · Cited by 159
BAYESIAN DECISION PROCEDURES FOR DOSE DETERMINING EXPERIMENTS
Whitehead, J., & Brunier, H. (1995) · Statistics in Medicine · doi:10.1002/sim.4780140904 · Cited by 144
Improved up‐and‐down designs for phase I trials
Ivanova, A., Montazer-Haghighi, A., Mohanty, S. G., & Durham, S. D. (2002) · Statistics in Medicine · doi:10.1002/sim.1336 · Cited by 131
Adaptive design improvements in the continual reassessment method for phase I studies
Heyd, J. M., & Carlin, B. P. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990615)18:11<1307::aid-sim128>3.0.co;2-x · Cited by 116
The continual reassessment method: comparison of Bayesian stopping rules for dose‐ranging studies
Zohar, S., & Chevret, S. (2001) · Statistics in Medicine · doi:10.1002/sim.920 · Cited by 105
Isotonic Designs for Phase I Trials
Leung, D. H. Y., & Wang, Y. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00132-x · Cited by 85
Patient specific dosing in a cancer phase I clinical trial
Babb, J. S., & Rogatko, A. (2001) · Statistics in Medicine · doi:10.1002/sim.848 · Cited by 85
Generalizing the TITE‐CRM to adapt for early‐ and late‐onset toxicities
Braun, T. (2005) · Statistics in Medicine · doi:10.1002/sim.2337 · Cited by 70
Accrual strategies for phase I trials with delayed patient outcome
Thall, P. F., Lee, J. J., Tseng, C., & Estey, E. H. (1999) · Statistics in Medicine · Cited by 60
New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I
Rogatko, A., Babb, J. S., Tighiouart, M., Khuri, F. R., & Hudes, G. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0458 · Cited by 54
Cited by
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Juric, D., Rodon, J., Tabernero, J., Janku, F., Burris, H. A., Schellens, J. H. M., Middleton, M. R., Berlin, J., Schuler, M., Gil-Martin, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7107 · Cited by 431
Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1963 · Cited by 418
Metadata
- Authors
- Neuenschwander, B., Branson, M., & Gsponer, T.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2008-03-14
- Volume
- 27
- Issue
- 13
- Pages
- 2420-2439
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2042990006
- Cited by
- 439
- References
- 22
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.